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Abstract 
Background: Arteriovenous (AV) fistula is the first choice of a long-term vascular access for hemodialysis, 
but there is a 20-30% probability of thrombosis in the 1st month after its creation. Ticlopidine is a potent drug, 
which inhibits both primary and secondary platelet aggregation. This study is performed to evaluate the effect 
of ticlopidine in the prevention of AV fistula. 
Methods:  yllaooT 124 patients in need of an AV fistula were divided into two groups after creation of their fistula. 
In the first group, we prescribed ticlopidine for 62 patients, and in the second group, 62 patients received placebo. 
The two groups were compared to see if their fistulas are patent or thrombotic after 1 and 3 months. 
Results: Of the 62 patients who received ticlopidine, four had fistula thrombosis, while in 62 patients who 
received placebo, 16 had fistula thrombosis (P = 0.003). This shows the significant effect of ticlopidine in the 
prevention of thrombosis in AV fistulas. Also, we compared age, sex, and the fistula location in the ticlopidine 
and placebo groups, and these attributes had no significant difference between the two groups (P > 0.050). 
Conclusions: Considering the significant value of ticlopidine in the prevention of AV fistula thrombosis, it can 
be recommended after the surgery if there is no contraindication for its use. 
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Introduction 
The arteriovenous (AV) fistula is the preferred type of 
vascular access because thrombosis rates, infection 
rates, access-related expenditures, and total health-care 
expenditures all are lower for patients with fistulas than 
for those with either synthetic AV grafts or central 
venous catheters (1-3). The first AV fistula was used in 
1966 (1), and it is still the first priority to have a long-
term vascular access for hemodialysis. However, a 
substantial problem is the fistula thrombosis during the 
first weeks after surgery (4,5). 
Antiplatelet agents such as acetylsalicylic acid and 
sulphinpyrazone have been used to prevent fistula 
thrombosis, but they have not shown favorable results  
(6-10). Ticlopidine is a potent inhibitor of both primary and 
secondary platelet aggregation (11,12). It reaches its peak 
effect in 5-6 days (13). In other studies, after 1 month of 
treatment with ticlopidine, the incidence of fistula in the 1st 
month has reduced from 30% in the placebo group to 10% 
in patients who received ticlopidine (14-17). 
Prevention of fistula thrombosis not only reduces 
the surgery’s adverse effects and the need to 
reoperation, but also it considerably reduces patient’s 
hospitalization time and costs. If ticlopidine gets 
approved in the prevention of early fistula thrombosis, 
it will be an important achievement in post-surgical 
care of hemodialysis patients. 
 
Materials and Methods 
The study population comprised 124 patients who were 
referred to a general hospital’s surgery ward for 
surgical application of an AV fistula between 2012 and 
2014. 61 patients were male and 63 were female. After 
proper explanation of the study and obtaining an 
informed consent, the patients were randomly divided 
into two groups: The first group of 62 patients received 
a 250 mg tablet of ticlopidine every 12 hours and the 
second group received placebo tablets. Generally, the 
patients were referred from nephrologists or general 
surgeons for kidney disorders which had caused them 
to be dependent on dialysis, or would have made them 
dialysis-dependent in the future.  
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The maximum age to enter the study was 85 years, 
and the patients who suffered from hepatic diseases, 
malignant hypertension, peptic or duodenum ulcers, or 
coagulopathies were excluded from the study. 
The patients were checked to see if their fistulas are 
patent or not, once 4 weeks after surgery and then again 
3 months after surgery. The fistula location was checked 
to see if there is a thrill, and the uncertain cases were 
evaluated by a radiologist using Doppler sonography. 
All surgeries were performed by a vascular surgeon in 
the hospital’s operation room. The patients whose fistula 
failed once could return to the study after a period of 3 
weeks. The type of study was interventional 
(randomized controlled trial). The drug (ticlopidine) and 
the placebo tablets were both produced in Iran by Osvah 
Pharmaceutical Company. The placebo tablets had the 
exact same look as the drug, and the costs were covered 
by the study’s sponsors.  
Sampling method: The patients were randomly 
designated to one of the groups using block randomization 
method. The order of patients was obtained from 
hospital’s research and development center in closed 
envelopes which were opened after the patient’s surgery. 
We used a unique file to store every patient’s data. The 
patient blinding process was as follows: None of the 
patients were aware if they are receiving a drug or 
placebo. The drug tablets and the placebo tablets had 
similar shape, packaging, taste, and color. 
Follow-up: The patients were followed up twice, 
once after 4 weeks and again after 3 months, in the 
vascular surgery clinic. The thrombosis was diagnosed 
by the vascular surgeon who performed the surgery, 
and if a patient did not have any thrill, he/she was 
referred to a radiologist to perform a Doppler 
sonography. The patients’ information involving their 
telephone numbers was registered, and if a patient did 
not come to the clinic for follow-up visits, the 
researcher contacted them and encouraged them to 
apply for a follow-up visit. 
Ethical considerations: The research was 
completely described to the patients, and written 
informed consents were obtained. The patients’ 
information remains confidential. The drug and 
placebo costs were provided by the study’s sponsors. 
Doppler sonography was performed only when there 
were scientific indications, and the patients did not 
need to pay for the test. The patients were able to leave 
the study whenever they wanted to. 
 
Results 
Of the 124 patients, 61 (49.2%) were male and 63 
(50.8%) were female. Minimum age was 19 years and 
maximum age was 79. The calculated chi-square test 
value was 0.857 for sex and 0.241 for age, which 
shows normal distribution of these attributes (Table 1). 
In the patients who received ticlopidine, 4 of the 62 
cases did not have a thrill after 1 month, which were 
confirmed to have a fistula thrombosis using Doppler 
sonography. In those who received placebo, 16 of the 
62 cases (25.8%) did not have a thrill after 1 month, 
and they also were all confirmed to have thrombosis by 
Doppler sonography. The P = 0.003, which shows a 
statistically significant difference between the two 
groups (Table 2). 
We compared age, sex, and the fistula location in 
the ticlopidine and placebo groups, and these attributes 
had no significant difference between the two groups 
(P > 0.050). 
We also compared the accompanying diseases 
(diabetes mellitus, hypertension, end-stage renal 
disease, and collagen vascular diseases) between the 
ticlopidine and placebo groups, and there were no 
significant difference between the groups (P > 0.050). 
Of all the patients, only 7 had collagen vascular 
diseases, so the P value was not reliable in this group 
of accompanying diseases. 
 
Discussion 
In this study, of the 62 patients who received 
ticlopidine, 4 had fistula thrombosis, while in the 
placebo group, 16 of the 62 patients had fistula 
thrombosis (P = 0.003), and the significant difference 
between the two groups justifies the prescription of 
ticlopidine to prevent AV fistula thrombosis. The 
sample size of the current study seems to be enough for 
that conclusion, considering the sample size of the 
previous studies. 
 
Table 1. Distribution of basic characteristics in the two studied groups 
Variables Levels 
Studied groups 
Total 
Case group Control group 
Mean age Year 53.16 50.48 51.82 
Age groups < 40 10 12 22 
40-50 14 21 35 
50-60 17 14 31 
> 60 21 15 36 
Sex Male 31 30 61 
Female 31 32 63 
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Table 2. Comparison of demographic and clinical variables between cases and controls 
Variables Levels 
Studied groups 
P-value 
Case group Control group 
Age Mean 53.16 50.48 0.241 
Age groups < 40 10 12 0.412 
40-50 14 21 
50-60 17 14 
> 60 21 15 
Sex Male 31 30 0.875 
Female 31 32 
Fistula location Cubital 58 51 0.048* 
Wrist 4 11 
DM Yes 48 40 0.083 
No 14 22 
HTN Yes 41 37 0.457 
No 21 25 
ESRD Yes 25 32 0.207 
No 37 30 
Lupus Yes 3 4 0.697 
No 59 58 
Thrill in the site of fistula Yes 58 46 0.003* 
No 4 16 
*Statistical significant. DM: Diabetes mellitus; HTN: Hypertension; ESRD: End-stage renal disease 
 
In the patients who had accompanying diseases 
(diabetes mellitus, hypertension, end-stage renal 
disease, and collagen vascular diseases), the incidence 
of fistula thrombosis was less in patients who 
received ticlopidine, but the difference between the 
groups of patients with different accompanying 
diseases was not significant. This shows that the 
incidence of AV fistula thrombosis does not correlate 
with the underlying disease, and the difference is 
because of the drug prescription. In the patients with 
collagen vascular diseases, fistula thrombosis 
occurred in none of the patients, but because of the 
few number of patients in this group, no reliable 
interpretation can be concluded for this group. Of the 
124 fistulas, only 15 of them were in the wrist region, 
and only one of these (in the placebo-receiving 
patients) resulted in fistula thrombosis. The number 
of fistulas in the wrist region is not sufficient to reach 
a reliable conclusion, and we need other studies to 
evaluate this type of fistulas. 
In the 1- and 3-month follow-ups, no patient had 
the adverse effects of ticlopidine, and so there was no 
need to discontinue the drug in any patient. The 
patients who had fistula thrombosis in their 1-month 
follow-up were excluded from the study and planned to 
undergo another surgery to create another AV fistula. 
After the surgery, they could be included in the study 
again. In the other studies, Grontoft et al. (13) 
evaluated the prescription of ticlopidine in AV fistula 
patients. The incidence of fistula thrombosis in patients 
who received ticlopidine was 11% and in the placebo 
group was 47%. There was statistically significant 
difference between the groups (P < 0.050) which shows 
the effectiveness of ticlopidine. 
In another study, Dember et al. (18) evaluated the 
effect of clopidogrel on patients with AV fistula. The 
incidence of thrombosis on the patients who received 
clopidogrel was 12.2%, and in the placebo-receiving 
group, it was 19.5% (P = 0.018). This study concluded 
that clopidogrel has significant effect on reducing 
fistula thrombosis incidence after the surgery. Dixon  
et al. (19) compared two groups of AV fistula patients. 
In one group, patients received ticlopidine and low-
dose aspirin, and in the other group, patients received 
placebo. Nearly 23% of the patients in the drug-
receiving group and 28% of patients in the placebo-
receiving group had fistula thrombosis (P = 0.030) 
which showed significant effect of ticlopidine and low-
dose aspirin in reducing fistula thrombosis incidence. 
We recommend more studies with sufficient sample 
size to evaluate early AV fistula thrombosis and its 
correlation with fistula region and also collagen 
vascular diseases. Also, more studies are recommended 
to evaluate the effect of anticoagulants on dialysis 
venous catheter and grafts. Aspirin is an inexpensive 
drug which can be accessed easily, but it has not been 
studied as much as ticlopidine and clopidogrel, and it 
can be recommended to study its effects on AV fistula 
after the surgery.  
Based on the finding of this study, due to the 
significant effect of ticlopidine in reducing the 
incidence of AV fistula thrombosis, we recommend its 
prescription after the surgery if there is no 
contraindication to use it. 
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